The GLP-1 Club
Intelligence Report
Every health club chain partnering, offering access to, or programming around GLP-1 weight loss medications — mapped and analyzed as of July 2026.
taken a GLP-1 (PRC, 2026)
by 2030 (JPMorgan)
a gym membership
(Planet Fitness, Q4 2025)
with active GLP-1 programs
Executive Summary
The convergence of GLP-1 medications and the fitness industry has moved from experiment to infrastructure. In the months since our Q1 edition, the story shifted from who is partnering to who is operating: the white-label in-club longevity clinics announced last quarter have opened their doors, a second oral GLP-1 pill won FDA approval, new "bridge" platforms made participation easier for mid-market operators, and the regulatory ground moved sharply under both compounders and the Medicare coverage timeline.
This report tracks 23 fitness clubs and 12 solution providers that have taken concrete action in the GLP-1 space as of July 2026 — up from 17 clubs and 10 providers in Q1. GLP-1 adoption itself keeps climbing: 13.2% of U.S. adults have now taken one, up from 12.4% last quarter and roughly double the rate of three years ago.
Key Findings
Bloodwork is becoming the standard-of-care line — and a growing liability for those skipping it. Concern is mounting industry-wide about members and telehealth patients starting GLP-1s without baseline labs. As ADA guidelines and FDA boxed-warning screening requirements come into sharper focus, this is shifting from a clinical best practice to a compliance exposure.
Longevity is going mainstream — and broader than GLP-1s. Operators are shifting from a GLP-1 focus to full-spectrum longevity offerings — hormone optimization, medical weight management, and anti-aging care — delivered through in-house or partnered clinical providers. Serotonin Centers, UFC GYM + NexGen MD, and NYSC + Thrive all now offer this bundled model.
The white-label clinic model is now live, not just announced. UFC GYM and NexGen MD Scientific opened their first two longevity clinics (Torrance and Corona, CA) in May, beginning a planned 24-month national rollout. Following Life Time's pioneering in-house Miora model, the white-label approach has now moved from press release to operating reality, alongside UFC GYM's global push into Spain and China.
A second oral pill changes the access equation. The FDA approved Lilly's Foundayo (orforglipron) on April 1 — the first small-molecule oral GLP-1 for weight loss with no food or water restrictions. Combined with oral Wegovy (Dec 2025), pills are lowering the friction that kept many members away from injectables.
An FDA panel backs six peptides for compounding — but a recommendation isn't a rule. The Pharmacy Compounding Advisory Committee voted to recommend BPC-157, KPV, TB-500, MOTS-C, epitalon, and semax for the 503A bulks list. The FDA isn't bound by it, and formal rulemaking could take 8–12 months or longer, pushing any change into 2027.
GLP-1 users need qualified fitness professionals — and the industry still lacks standardized education. Every program in this report points to the same trainer readiness gap: muscle preservation, energy management, nutrition guidance, side-effect awareness, behavioral coaching, and scope of practice all require training most staff don't yet have.
Integration Model Framework
Health clubs approach GLP-1 integration along a spectrum. Understanding where each model sits helps operators evaluate which approach fits their brand, resources, and risk tolerance.
Key Solution Providers
B2B platforms providing clinical, regulatory, and technology infrastructure for fitness clubs entering the GLP-1 space.
The GLP-1 Club Tracker
Selected health club and boutique fitness brands with concrete GLP-1 action as of July 2026.
Note: Location counts are approximate. Integration type reflects the primary current model; some operators run more than one.
New This Quarter
April 1, 2026
FDA Approves Foundayo (orforglipron)
Lilly's once-daily oral GLP-1 is the first small-molecule pill for weight loss with no food or water restrictions, distinct from oral semaglutide. Available via LillyDirect from April 6, then retail and telehealth.
July 23, 2026
Lilly's retatrutide posts the largest weight-loss results yet
Two additional Phase 3 trials showed average weight loss of up to 20.8% (TRIUMPH-2) and 22.6% (TRIUMPH-3) at the highest dose of the triple-hormone-receptor agonist — ahead of any GLP-1 on the market today. Lilly plans to file for FDA approval in Q1 2027; it remains investigational and years from club-level relevance.
July 23–24, 2026
FDA advisory panel recommends six peptides for compounding
The Pharmacy Compounding Advisory Committee voted to recommend adding BPC-157, KPV, TB-500, MOTS-C, epitalon, and semax to the 503A bulks list, which would let compounding pharmacies prepare them against a patient-specific prescription. The vote isn't binding on the FDA, and any change requires a formal notice-and-comment rulemaking process expected to take 8–12 months or longer, pushing a possible outcome into 2027.
May 2026
UFC GYM + NexGen MD Clinics Open
The Q1 joint venture went operational with two flagship in-club longevity clinics in Torrance and Corona, CA, offering FDA-approved GLP-1s, peptides, and HRT. First of a 24-month national rollout. UFC GYM is simultaneously expanding globally (Spain via CR7 conversions, plus mainland China).
May 2026
Serotonin Centers Opens Lake Nona Longevity Clinic
The physician-led longevity franchise founded by Retro Fitness founder Eric Casaburi opened a Lake Nona, FL center (its 15th nationwide, with 80+ in development). The cash-pay, concierge model spans medical weight management (including GLP-1s), hormone optimization, peptide therapy, IV therapy, and recovery services. Standalone longevity clinics are scaling fast right next to fitness, competing for the same metabolically focused members clubs are courting.
March 2026
New York Sports Club + Thrive
NYSC partnered with Thrive to give members access to biomarker testing, longevity care, hormone balance, and GLP-1 weight-loss treatment across its NY, Boston, Philadelphia, and DC footprint — a retention-driven referral play that adds clinical value without complicating club operations.
2026
Longevity Is the Destination; GLP-1 Was the On-Ramp
Operators are shifting from a GLP-1 focus to full-spectrum longevity offerings — hormone optimization (HRT/TRT), medical weight management, and anti-aging care — delivered through in-house or partnered clinical providers. Serotonin Centers, UFC GYM + NexGen MD, and NYSC + Thrive all bundle hormones and longevity care around GLP-1s.
2026
Orangetheory 2026 Transformation Challenge
OTF oriented its flagship challenge around GLP-1 users' fitness needs (muscle preservation, structured progression).
2026
Baseline Bloodwork Becomes the Standard-of-Care Line
ADA Standards of Care 2025 define a baseline metabolic panel (A1C, lipids, creatinine/eGFR, urine albumin-to-creatinine ratio, liver/FIB-4, CBC) at the initial visit, while semaglutide's FDA boxed warning mandates contraindication screening for medullary thyroid carcinoma, MEN2, and pancreatitis history — a growing compliance liability for programs that skip it.
2026
UK Data: GLP-1 Users Are Spending More on Fitness, Not Less
A PwC survey of 2,300+ UK adults found 27% of current/former GLP-1 users increased fitness spending during treatment (vs. just 5% who cut back). Among those spending more: 41% joined a gym or started classes, 20% shifted toward strength training, and 16% hired a personal trainer.
2026
US Data: GLP-1 Fitness Impact Is Uneven by Category
A second PwC survey of 3,089 U.S. consumers found GLP-1 adoption has doubled to 21% of U.S. households (from 9% in January 2025). Cardio is the clear winner (36% increased frequency), strength training grew modestly (21% increased), but group fitness classes are under pressure. 85% of users say companies still aren't meeting their needs.
2026
Broader Market Context: Strength Training Has Caught Up to Cardio
Harrison Co.'s "How America Moves" report found 86% of active Americans exercise at least weekly, with strength training now essentially tied with cardio as the most common training type (66% vs. 65%) and wearable usage at 75%. The report doesn't address GLP-1s directly, but the trends track closely with what operators are already building for GLP-1 and longevity members.
The Trainer Readiness Gap
Every program in this report emphasizes the same thing: GLP-1 users need qualified fitness professionals. Yet the industry lacks standardized education.
What Trainers Need to Know
Muscle preservation: Up to 50% of weight lost can be lean mass without resistance training. Progressive overload is essential.
Energy management: GLP-1s suppress appetite. Clients may be under-fueled. Adjust intensity, volume, timing.
Nutrition guidance: High-protein intake critical. Know when to guide vs. refer to a registered dietitian.
Side effect awareness: Nausea, fatigue, GI distress, dehydration. Know when to modify or refer.
Behavioral coaching: Many GLP-1 users are first-time gym-goers. Welcoming experience drives retention.
Scope of Practice: Understanding the boundary between fitness coaching and medical advice to ensure member safety and brand liability protection.
Closing the Trainer Readiness Gap
To address the "Trainer Readiness Gap," Inspire360 is launching a premier specialty certification developed in partnership with leading clinical experts to provide clinician-backed education for fitness professionals. This comprehensive solution, alongside targeted CEC courses, equips trainers with the critical scope of practice physiological protocols needed to safely manage the unique needs of members on GLP-1 medications. By bridging this expertise gap, you ensure your staff can confidently deliver the resistance training and metabolic guidance essential for preventing muscle loss and driving long-term member results.
If there is a program we have missed, please let us know by emailing Kelli Pease at kelli@inspire360.com.
Methodology & Sources
Compiled from FDA and CMS announcements, company earnings calls, press releases, SEC filings, industry media, and verified reporting through July 2026. This report does not constitute investment, legal, or medical advice.
Next edition: Q3 2026 (est. September 2026).
View all GLP-1 past quarterly reports here.
